AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06077409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gentle Human Touch
Description: Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
Study NCT05140694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
Study NCT05140694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
Study NCT05140694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin and Dulaglutide
Description: Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
Study NCT05335967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program
Description: The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
Study NCT05335967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information package
Description: The patients in this group will receive an information package on a healthy diet.
Study NCT04681469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months.
Study NCT06141291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
Study NCT06141291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OGTT
Description: Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
Study NCT06141291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
Study NCT05972538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osstell ( Osstell AB, Goteborg, Sweden).
Description: Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
Study NCT05972538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osstell ( Osstell AB, Goteborg, Sweden).
Description: Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
Study NCT05972538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein
Description: Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
Study NCT05972538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein
Description: Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
Study NCT05972538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire for patient satisfaction
Description: A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
Study NCT05972538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire for patient satisfaction
Description: A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
Study NCT06146907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive motor dual task exercises
Description: exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
Study NCT06146907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exergaming
Description: Nintendo switch games that involve physical activity by participants to complete
Study NCT04855474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
Study NCT05271630 — intervention group
Intervention type: OTHER
Intervention: Autologous Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
Study NCT05271630 — intervention group
Intervention type: DRUG
Intervention: Immunomodulatory Agent
Description: ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
Study NCT05271630 — intervention group
Intervention type: DRUG
Intervention: Proteasome Inhibitor
Description: ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
Study NCT06321601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Oral administration
Study NCT04605341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miniplate
Description: comparison between k wires and miniplate in metacarpal fractures
Study NCT05521828 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin delta (Rekovelle)
Description: 12 mcg/day will be used for ovarian stimulation in both arms
Study NCT05521828 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duphaston
Description: 20 mg/day will be used for pituitary suppression in both arms
Study NCT05521828 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GnRH agonist (Gonapeptyl)
Description: (2 ampules:0.2 mg) will be used for ovulation triggering in both arms
Study NCT05333705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of natural killer cells
Description: Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
Study NCT06221826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexidol
Description: Neurocytoprotector
Study NCT06066008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-01-L
Description: rAAV-hRS1 intravitreal injection of low dose
Study NCT06066008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-01-H
Description: rAAV-hRS1 intravitreal injection of high dose
Study NCT04927585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid
Study NCT04927585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid
Study NCT04927585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study NCT06202781 — intervention group
Intervention type: DRUG
Intervention: SOX plus PD-1 inhibitor
Description: S-1, Oxaliplatin and nivolumab/sintilimab
Study NCT06202781 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopic biopsy
Description: Gastroscopy and biopsy
Study NCT05252663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quake device training
Description: In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
Study NCT05252663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: postural drainage - percussion
Study NCT05777512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Feeds
Description: The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
Study NCT05777512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Feeds
Description: The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
Study NCT05118334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study NCT05118334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study NCT05574842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double duty interventions using nutrition behavior change communication approach
Description: The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
Study NCT06523244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHOTODYNAMIC THERAPY
Description: Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
Study NCT06523244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHOTODYNAMIC THERAPY
Description: Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
Study NCT04575207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: caFFR
Description: caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off > 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
Study NCT04575207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
Study NCT05921253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARASYM neuromodulation device
Description: Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
Study NCT05921253 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PARASYM neuromodulation device
Description: Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
Study NCT05464615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
Study NCT05111691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling
Study NCT05624346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep-Breathing Exercises
Description: In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
Study NCT04828889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal dilators
Description: Anal sphincter training for relaxation
Study NCT04828889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy
Description: lateral internal sphincterotomy is a firmly established method for treating anal fissures.
Study NCT04927585 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
Study NCT05311696 — intervention group
Intervention type: OTHER
Intervention: psychoeducation
Description: The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
Study NCT05851027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study NCT04960592 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Temporary implantation of a clinical available neurostimulator.
Study NCT04884711 — intervention group
Intervention type: OTHER
Intervention: No Interventions. Participants will be using their everyday digital health technologies.
Description: The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
Study NCT04884711 — intervention group
Intervention type: OTHER
Intervention: In depth Interviews
Description: In-depth interviews will be conducted to gather lived experiences of homebound older people.
Study NCT04884711 — intervention group
Intervention type: OTHER
Intervention: Focus Group Discussions
Description: Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
Study NCT05064956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle.
Study NCT04988919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4D
Description: multi-ingredient supplement mixed with 24 ounces of water
Study NCT04988919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: taste-matched placebo mixed with 24 ounces of water
Study NCT04255251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diammine Fluoride
Description: Subjects will receive SDF around their crown margins every 6 months for next 3 years.
Study NCT04255251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Subjects will receive SDF around their crown margins every 6 months for next 3 years.
Study NCT06325605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Description: 3 capsules, 3 times a day, for 8 consecutive weeks
Study NCT06325605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks.
Study NCT06325605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Oxalate
Description: Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
Study NCT06208540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
Study NCT06208540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olfactory and gustatory trainings
Description: olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
Study NCT06208540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: olfactory and gustatory trainings
Description: olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
Study NCT04420494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.